{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:57:51Z","timestamp":1778295471662,"version":"3.51.4"},"reference-count":67,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Alopecia areata (AA) is a common autoimmune-mediated hair loss disorder in humans with an estimated lifetime risk of approximately 2\u2009%. Episodes of hair loss usually begin with isolated hairless patches that may progress to complete hair loss over the entire body. A familial occurrence of AA is well established, with recurrence risks of about 6\u20138\u2009% in first-degree relatives. AA is a multifactorial disorder involving both environmental and genetic risk factors. Previous research has identified 14 susceptibility loci, most of which implicate genes involved in the immune response. The following review presents a summary of the latest findings from genome-wide association, sequencing and gene expression studies of AA, as well as their contribution to the recent therapeutic developments.<\/jats:p>","DOI":"10.1515\/medgen-2023-2004","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T07:30:04Z","timestamp":1680679804000},"page":"15-22","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances in the genetics of alopecia areata"],"prefix":"10.1515","volume":"35","author":[{"given":"F.","family":"Buket Basmanav","sequence":"first","affiliation":[{"name":"University of Bonn Institute of Human Genetics, Medical Faculty & University Hospital Bonn Venusberg Campus 1, Geb\u00e4ude 13 Bonn Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-3623","authenticated-orcid":false,"given":"Regina C.","family":"Betz","sequence":"additional","affiliation":[{"name":"University of Bonn Institute of Human Genetics, Medical Faculty & University Hospital Bonn Venusberg Campus 1, Geb\u00e4ude 13 Bonn Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"2024080710230555156_j_medgen-2023-2004_ref_001","doi-asserted-by":"crossref","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR: Lifetime incidence risk of alopecia areata estimated at 2.1\u2009% by Rochester Epidemiology Project, 1990\u20132009. J Invest Dermatol 2014, 134(4):1141\u20131142.","DOI":"10.1038\/jid.2013.464"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_002","unstructured":"Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM: Association Between Alopecia Areata, Anxiety, and Depression: A Systematic Review and Meta-analysis. J. Am. Acad. Dermatol 2019, S0190-9622(19)30890-30894."},{"key":"2024080710230555156_j_medgen-2023-2004_ref_003","doi-asserted-by":"crossref","unstructured":"Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, Becker T, Heilmann S, Yamany T, Duvic M et al: Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 2015, 6:5966.","DOI":"10.1038\/ncomms6966"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_004","doi-asserted-by":"crossref","unstructured":"Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV et al: Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466(7302):113\u2013117.","DOI":"10.1038\/nature09114"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_005","doi-asserted-by":"crossref","unstructured":"Erjavec SO, Gelfman S, Abdelaziz AR, Lee EY, Monga I, Alkelai A, Ionita-Laza I, Petukhova L, Christiano AM: Whole exome sequencing in Alopecia Areata identifies rare variants in KRT82. Nat Commun 2022, 13(1):800.","DOI":"10.1038\/s41467-022-28343-3"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_006","doi-asserted-by":"crossref","unstructured":"Folster-Holst R, Rohrer T, Jung AM: Dermatological aspects of the S2k guidelines on Down syndrome in childhood and adolescence. J Dtsch Dermatol Ges 2018, 16(10):1289\u20131295.","DOI":"10.1111\/ddg.13665"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_007","doi-asserted-by":"crossref","unstructured":"Senna M, Ko J, Tosti A, Edson-Heredia E, Fenske DC, Ellinwood AK, Rueda MJ, Zhu B, King B: Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims. Adv Ther 2021, 38(9):4646\u20134658.","DOI":"10.1007\/s12325-021-01845-0"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_008","doi-asserted-by":"crossref","unstructured":"Hordinsky M, Ericson M: Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc 2004, 9(1):73\u201378.","DOI":"10.1111\/j.1087-0024.2004.00835.x"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_009","doi-asserted-by":"crossref","unstructured":"Paus R, Bulfone-Paus S, Bertolini M: Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management. J Investig Dermatol Symp Proc 2018, 19(1):S12-S17.","DOI":"10.1016\/j.jisp.2017.10.014"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_010","unstructured":"Alexis AF, Dudda-Subramanya R, Sinha AA: Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol 2004, 14(6):364\u2013370."},{"key":"2024080710230555156_j_medgen-2023-2004_ref_011","doi-asserted-by":"crossref","unstructured":"Basmanav FB, Betz RC: Translational impact of omics studies in alopecia areata: recent advances and future perspectives. Expert Rev Clin Immunol 2022, 18(8):845\u2013857.","DOI":"10.1080\/1744666X.2022.2096590"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_012","doi-asserted-by":"crossref","unstructured":"Wang ECE, Dai Z, Christiano AM: Novel therapies for alopecia areata: The era of rational drug development. J Allergy Clin Immunol 2018, 141(2):499\u2013504.","DOI":"10.1016\/j.jaci.2017.10.028"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_013","doi-asserted-by":"crossref","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L et al: Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014, 20(9):1043\u20131049.","DOI":"10.1038\/nm.3645"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_014","doi-asserted-by":"crossref","unstructured":"Dillon KL: A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clin Cosmet Investig Dermatol 2021, 14:691\u2013714.","DOI":"10.2147\/CCID.S309215"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_015","doi-asserted-by":"crossref","unstructured":"Ismail FF, Sinclair R: JAK inhibition in the treatment of alopecia areata \u2013 a promising new dawn? Expert Rev Clin Pharmacol 2020, 13(1):43\u201351.","DOI":"10.1080\/17512433.2020.1702878"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_016","doi-asserted-by":"crossref","unstructured":"King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, McCollam J, Gamalo M, Janes J, Edson-Heredia E et al: Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. J Am Acad Dermatol 2021, 85(4):847\u2013853.","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_017","doi-asserted-by":"crossref","unstructured":"Steele L, Lee HL, Maruthappu T, O\u2019Toole EA: The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked? Clin Exp Dermatol 2021, 46(7):1290\u20131292.","DOI":"10.1111\/ced.14615"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_018","doi-asserted-by":"crossref","unstructured":"Yu DA, Kim YE, Kwon O, Park H: Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol 2021, 87(5):621\u2013627.","DOI":"10.25259\/IJDVL_975_19"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_019","doi-asserted-by":"crossref","unstructured":"Phan K, Sebaratnam DF: JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019, 33(5):850\u2013856.","DOI":"10.1111\/jdv.15489"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_020","doi-asserted-by":"crossref","unstructured":"Gilhar A, Keren A, Paus R: JAK inhibitors and alopecia areata. Lancet 2019, 393(10169):318\u2013319.","DOI":"10.1016\/S0140-6736(18)32987-8"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_021","doi-asserted-by":"crossref","unstructured":"Blaumeiser B, van der Goot I, Fimmers R, Hanneken S, Ritzmann S, Seymons K, Betz RC, Ruzicka T, Wienker TF, De Weert J et al: Familial aggregation of alopecia areata. J. Am. Acad. Dermatol 2006, 54(4):627\u2013632.","DOI":"10.1016\/j.jaad.2005.12.007"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_022","doi-asserted-by":"crossref","unstructured":"Betz RC, Hillmer AM, N\u00f6then MM: Genetik der Alopecia areata. medgen 2007, 19:356\u2013360.","DOI":"10.1007\/s11825-007-0035-1"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_023","doi-asserted-by":"crossref","unstructured":"Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, Stenn K: Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J. Am. Acad. Dermatol.1999, 40(2 Pt 1):242\u2013246.","DOI":"10.1016\/S0190-9622(99)70195-7"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_024","doi-asserted-by":"crossref","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, Duvic M, King LE, Jr., McMichael AJ, Randall VA et al: Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J. Am. Acad. Dermatol 2004, 51(3):440\u2013447.","DOI":"10.1016\/j.jaad.2003.09.032"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_025","doi-asserted-by":"crossref","unstructured":"John KK, Brockschmidt FF, Redler S, Herold C, Hanneken S, Eigelshoven S, Giehl KA, De Weert J, Lutz G, Kruse R et al: Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol 2011, 131(5):1169\u20131172.","DOI":"10.1038\/jid.2010.427"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_026","doi-asserted-by":"crossref","unstructured":"Monteleone G, Pallone F, Macdonald TT: Interleukin\u201321 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci 2009, 30(8):441\u2013447.","DOI":"10.1016\/j.tips.2009.05.006"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_027","doi-asserted-by":"crossref","unstructured":"Eagle RA, Trowsdale J: Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007, 7(9):737\u2013744.","DOI":"10.1038\/nri2144"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_028","doi-asserted-by":"crossref","unstructured":"Moftah NH, El-Barbary RA, Rashed L, Said M: ULBP3: a marker for alopecia areata incognita. Arch Dermatol Res 2016, 308(6):415\u2013421.","DOI":"10.1007\/s00403-016-1652-9"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_029","doi-asserted-by":"crossref","unstructured":"Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M, Paus R: Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008, 128(5):1196\u20131206.","DOI":"10.1038\/sj.jid.5701183"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_030","doi-asserted-by":"crossref","unstructured":"Jagielska D, Redler S, Brockschmidt FF, Herold C, Pasternack SM, Garcia Bartels N, Hanneken S, Eigelshoven S, Refke M, Barth S et al: Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol 2012, 132(9):2192\u20132197.","DOI":"10.1038\/jid.2012.129"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_031","doi-asserted-by":"crossref","unstructured":"Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D: Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009, 106(32):13439\u201313444.","DOI":"10.1073\/pnas.0901965106"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_032","doi-asserted-by":"crossref","unstructured":"Battaglia M, Roncarolo MG: The Tregs\u2019 world according to GARP. Eur J Immunol 2009, 39(12):3296\u20133300.","DOI":"10.1002\/eji.200940117"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_033","doi-asserted-by":"crossref","unstructured":"Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M et al: Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007, 80(2):316\u2013328.","DOI":"10.1086\/511442"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_034","doi-asserted-by":"crossref","unstructured":"Lee S, Paik SH, Kim HJ, Ryu HH, Cha S, Jo SJ, Eun HC, Seo JS, Kim JI, Kwon OS: Exomic sequencing of immune-related genes reveals novel candidate variants associated with alopecia universalis. PLoS One 2013, 8(1):e53613.","DOI":"10.1371\/journal.pone.0053613"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_035","doi-asserted-by":"crossref","unstructured":"Shin JM, Kim KH, Kim SM, Hong D, Park J, Lee HY, Lim WJ, Shin YA, Kim CD, Seo YJ et al: Exome sequencing reveals novel candidate gene variants associated with clinical characteristics in alopecia areata patients. J Dermatol Sci 2020, 99(3):216\u2013220.","DOI":"10.1016\/j.jdermsci.2020.08.003"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_036","doi-asserted-by":"crossref","unstructured":"Schweizer J, Langbein L, Rogers MA, Winter H: Hair follicle-specific keratins and their diseases. Exp Cell Res 2007, 313(10):2010\u20132020.","DOI":"10.1016\/j.yexcr.2007.02.032"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_037","doi-asserted-by":"crossref","unstructured":"Betz RC, Cabral RM, Christiano AM, Sprecher E: Unveiling the roots of monogenic genodermatoses: genotrichoses as a paradigm. J Invest Dermatol 2012, 132(3 Pt 2):906\u2013914.","DOI":"10.1038\/jid.2011.408"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_038","doi-asserted-by":"crossref","unstructured":"Petukhova L, Patel AV, Rigo RK, Bian L, Verbitsky M, Sanna-Cherchi S, Erjavec SO, Abdelaziz AR, Cerise JE, Jabbari A et al: Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy. Exp Dermatol 2020, 29(3):243\u2013253.","DOI":"10.1111\/exd.13986"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_039","doi-asserted-by":"crossref","unstructured":"Fischer J, Degenhardt F, Hofmann A, Redler S, Basmanav FB, Heilmann-Heimbach S, Hanneken S, Giehl KA, Wolff H, Moebus S et al: Genomewide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. Exp Dermatol 2017, 26(6):536\u2013541.","DOI":"10.1111\/exd.13123"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_040","doi-asserted-by":"crossref","unstructured":"An S, Cutler G, Zhao JJ, Huang SG, Tian H, Li W, Liang L, Rich M, Bakleh A, Du J et al: Identification and characterization of a melanin-concentrating hormone receptor. Proc Natl Acad Sci U S A 2001, 98(13):7576\u20137581.","DOI":"10.1073\/pnas.131200698"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_041","doi-asserted-by":"crossref","unstructured":"Suarez-Farinas M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, Czernik A, Zheng X, Estrada YD, Xu HJE et al: Alopecia areata profiling shows TH1, TH2, and IL\u201323 cytokine activation without parallel TH17\/TH22 skewing. J Allergy Clin Immunol 2015, 136(5):1277\u20131287.","DOI":"10.1016\/j.jaci.2015.06.032"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_042","doi-asserted-by":"crossref","unstructured":"Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, Hordinsky M, Norris D, Clynes R, Christiano AM: Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine 2016, 7:240\u2013247.","DOI":"10.1016\/j.ebiom.2016.03.036"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_043","doi-asserted-by":"crossref","unstructured":"McPhee CG, Duncan FJ, Silva KA, King LE, Jr., Hogenesch H, Roopenian DC, Everts HB, Sundberg JP: Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse. J Invest Dermatol 2012, 132(6):1736\u20131738.","DOI":"10.1038\/jid.2012.17"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_044","doi-asserted-by":"crossref","unstructured":"Subramanya RD, Coda AB, Sinha AA: Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics 2010, 96(3):146\u2013153.","DOI":"10.1016\/j.ygeno.2010.05.002"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_045","doi-asserted-by":"crossref","unstructured":"Carroll JM, McElwee KJ, L EK, Byrne MC, Sundberg JP: Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 2002, 119(2):392\u2013402.","DOI":"10.1046\/j.1523-1747.2002.01811.x"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_046","doi-asserted-by":"crossref","unstructured":"Chen JC, Cerise JE, Jabbari A, Clynes R, Christiano AM: Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution. Cell Syst 2015, 1(5):326\u2013337.","DOI":"10.1016\/j.cels.2015.11.001"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_047","unstructured":"Nusslein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K et al: Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol 2016, 34(3):489\u2013499."},{"key":"2024080710230555156_j_medgen-2023-2004_ref_048","doi-asserted-by":"crossref","unstructured":"Sundberg JP, McElwee KJ, Carroll JM, King LE, Jr.: Hypothesis testing: CTLA4 co-stimulatory pathways critical in the pathogenesis of human and mouse alopecia areata. J Invest Dermatol 2011, 131(11):2323\u20132324.","DOI":"10.1038\/jid.2011.203"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_049","doi-asserted-by":"crossref","unstructured":"Mackay-Wiggan J, Sallee BN, Wang EHC, Sansaricq F, Nguyen N, Kim C, Chen JC, Christiano AM, Clynes R: An open-label study evaluating the efficacy of abatacept in alopecia areata. J Am Acad Dermatol 2021, 84(3):841\u2013844.","DOI":"10.1016\/j.jaad.2020.09.091"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_050","doi-asserted-by":"crossref","unstructured":"Czarnowicki T, He HY, Wen HC, Hashim PW, Nia JK, Malik K, Estrada Y, Kimmel GW, Taliercio M, Krueger JG et al: Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations. Allergy 2018, 73(3):713\u2013723.","DOI":"10.1111\/all.13346"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_051","doi-asserted-by":"crossref","unstructured":"Fuentes-Duculan J, Gulati N, Bonifacio KM, Kunjravia N, Zheng X, Suarez-Farinas M, Shemer A, Guttman-Yassky E, Krueger JG: Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol 2016, 25(4):282\u2013286.","DOI":"10.1111\/exd.12918"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_052","doi-asserted-by":"crossref","unstructured":"Kridin K, Renert-Yuval Y, Guttman-Yassky E, Cohen AD: Alopecia Areata Is Associated with Atopic Diathesis: Results from a Population-Based Study of 51.561 Patients. J Allergy Clin Immunol Pract 2020, 8(4):1323\u20131328 e1321.","DOI":"10.1016\/j.jaip.2020.01.052"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_053","doi-asserted-by":"crossref","unstructured":"Song T, Pavel AB, Wen HC, Malik K, Estrada Y, Gonzalez J, Hashim PW, Nia JK, Baum D, Kimmel G et al: An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. J Allergy Clin Immunol 2018, 142(5):1631\u20131634 e1613.","DOI":"10.1016\/j.jaci.2018.06.029"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_054","doi-asserted-by":"crossref","unstructured":"Bain KA, McDonald E, Moffat F, Tutino M, Castelino M, Barton A, Cavanagh J, Ijaz UZ, Siebert S, McInnes IB et al: Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol 2020, 182(1):130\u2013137.","DOI":"10.1111\/bjd.18008"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_055","doi-asserted-by":"crossref","unstructured":"Smogorzewski J, Sierro T, Compoginis G, Kim G: Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep 2019, 5(2):116\u2013117.","DOI":"10.1016\/j.jdcr.2018.11.007"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_056","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, Sullivan-Whalen M, Singer GK, Garcet S, Pavel AB et al: Phase 2a randomized clinical trial of dupilumab (anti-IL\u20134Ralpha) for alopecia areata patients. Allergy 2022, 77(3):897\u2013906.","DOI":"10.1111\/all.15071"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_057","doi-asserted-by":"crossref","unstructured":"Ortolan LS, Kim SR, Crotts S, Liu LY, Craiglow BG, Wambier C, Paschoal RS, King BA, Jabbari A: IL\u201312\/IL\u201323 neutralization is ineffective for alopecia areata in mice and humans. J Allergy Clin Immunol 2019, 144(6):1731\u20131734 e1731.","DOI":"10.1016\/j.jaci.2019.08.014"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_058","doi-asserted-by":"crossref","unstructured":"Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R et al: A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res 2019, 311(1):29\u201336.","DOI":"10.1007\/s00403-018-1876-y"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_059","doi-asserted-by":"crossref","unstructured":"Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, Borbon J, Clynes R, Christiano AM, Mackay-Wiggan J: An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. J Invest Dermatol 2018, 138(7):1539\u20131545.","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_060","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA et al: Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol 2022, 149(4):1318\u20131328.","DOI":"10.1016\/j.jaci.2021.10.036"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_061","doi-asserted-by":"crossref","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC et al: Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016, 1(15):e89776.","DOI":"10.1172\/jci.insight.89776"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_062","doi-asserted-by":"crossref","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R: Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 2016, 1(15):e89790.","DOI":"10.1172\/jci.insight.89790"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_063","doi-asserted-by":"crossref","unstructured":"Chen JC, Dai Z, Christiano AM: Regulatory network analysis defines unique drug mechanisms of action and facilitates patient-drug matching in alopecia areata clinical trials. Comput Struct Biotechnol J 2021, 19:4751\u20134758.","DOI":"10.1016\/j.csbj.2021.08.026"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_064","doi-asserted-by":"crossref","unstructured":"Petukhova L: An Imperative Need for Further Genetic Studies of Alopecia Areata. J Investig Dermatol Symp Proc 2020, 20(1):S22-S27.","DOI":"10.1016\/j.jisp.2020.04.003"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_065","doi-asserted-by":"crossref","unstructured":"Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R: Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol 2020, 29(8):703\u2013725.","DOI":"10.1111\/exd.14155"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_066","doi-asserted-by":"crossref","unstructured":"Paus R, Bulfone-Paus S, Bertolini M: Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management. J Investig Dermatol Symp Proc 2018, 19(1):S12-S17.","DOI":"10.1016\/j.jisp.2017.10.014"},{"key":"2024080710230555156_j_medgen-2023-2004_ref_067","doi-asserted-by":"crossref","unstructured":"Borcherding N, Crotts SB, Ortolan LS, Henderson N, Bormann NL, Jabbari A: A transcriptomic map of murine and human alopecia areata. JCI Insight 2020, 5(13):e137424.","DOI":"10.1172\/jci.insight.137424"}],"container-title":["Medizinische Genetik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/medgen-2023-2004\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/medgen-2023-2004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:30:49Z","timestamp":1723026649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/medgen-2023-2004\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4,5]]},"published-print":{"date-parts":[[2023,4,3]]}},"alternative-id":["10.1515\/medgen-2023-2004"],"URL":"https:\/\/doi.org\/10.1515\/medgen-2023-2004","relation":{},"ISSN":["1863-5490","0936-5931"],"issn-type":[{"value":"1863-5490","type":"electronic"},{"value":"0936-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,3]]}}}